No Data
Jiansheng Technology-B (09877.HK) will hold a Board of Directors meeting on March 21 to approve the annual performance.
On March 11, Glonghui announced that Jianshi Technology-B (09877.HK) will hold a Board of Directors meeting on March 21, 2025, to review and approve (including) the annual performance of the company and its subsidiaries for the year ending December 31, 2024, and the proposed final dividend distribution (if any).
JENSCARE-B: NOTICE OF BOARD MEETING
The new drug development time is cut in half, diagnoses are more accurate, industry barriers are lowered... AI is transforming the Medical Industry in China.
On February 26, Deutsche Bank Analyst Cyrus Ng released a report stating that the entire Medical Industry in China, from drug development and diagnostics to Hospital management, will benefit from the AI revolution.
The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus
① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.
AI hotspots continue to boost! Most Medical stocks in Hong Kong strengthen, with Micro-invasion Siasun Robot&Automation rising over 20%.
How does Sister Wood perceive this hot topic of AI Medical? What positive impacts will the emergence of DeepSeek bring to the medical field?
Jenscare Scientific: Pan Fei Appointed as CEO
Pleasing Signs As A Number Of Insiders Buy Jenscare Scientific Stock
